Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved by the Danish ...

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5BOCA RATON, ...

Citi raised the firm’s price target on Exelixis (EXEL) to $45 from $38 and keeps a Buy rating on the shares following the Q4 report. The ...

A new study by UC San Francisco found that prostate cancer cases are increasing in California, likely due to a change in ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Cases of prostate cancer are on the rise in California, according to new research. A study by UC San Francisco (UCSF) included nearly 388,000 men who had prostate cancer between 2004 and 2021.

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...

Veracyte, Inc. , a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU). The findings ...

Advanced prostate cancer cases are rising sharply in California, outpacing national trends, according to a new study from ...